Oncobit

At Oncobit, our aim is to precisely monitor individual cancer markers for an optimal therapy management. At Oncobit, we are driven by the commitment to improve patient care in the face of cancer’s challenges and uncertainties. Our mission revolves around the precise monitoring of individual cancer markers to achieve optimal therapy management and successful treatment outcomes. At Oncobit, we aim to improve patient outcomes with high-precision and cutting-edge cancer monitoring solutions. Oncobit™ PM is a data-driven cancer monitoring platform for the sensitive and quantitative detection of specific cancer markers in circulating tumor-derived DNA (ctDNA) from the blood. We are proud to share that our Oncobit™ PM ctDNA analysis tests are now in use at three prominent cancer centers across Germany, including the University Medical Center Hamburg-Eppendorf (UKE) led by Prof. Our advanced Oncobit PM tests play a pivotal role in addressing various issues related to cancer monitoring. We are thrilled to announce that we have signed a service agreement with Immunocore Holdings plc (NASDAQ: IMCR), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases.